New survey finds women who suffer from migraines want a better
understanding of migraine triggers
PARSIPPANY, N.J., Nov. 14, 2012 /PRNewswire/ -- Ninety percent
of women who suffer from migraines agree that with an increased
understanding of the triggers, they can better manage their
migraines, according to a survey1 conducted by Novartis
Consumer Health, Inc., the makers of Excedrin®
Migraine.
That is why today, the makers of Excedrin® Migraine
have joined with singer, actress and Broadway star, Jordin Sparks, and well-known Lenox Hill
Hospital internist Keri Peterson, MD
– both migraine sufferers – to launch, "Managing Migraines: Know
Your Triggers. Know Your Treatment," a new education campaign. It's
designed to raise awareness of the importance of tracking migraine
triggers so sufferers can better manage their migraines.
While certain triggers may increase the risk of a migraine,
triggers vary from person to person. According to the women
surveyed, 83% said they would like better tools to help them track
the triggers that lead to their migraines so that they can better
manage attacks.
To help migraine sufferers, Excedrin® Migraine has
developed a convenient, new tracking tool, My Migraine Triggers™
App, with a neurologist. Available for free on iTunes, this
app allows migraine sufferers to track the causes of their
migraines and share them with their physician. Migraine
sufferers can chart out a daily log of information into
customizable reports to easily understand which activities, foods
and beverages are associated with the onset of their headaches
"As they say in my business ... the show must go on.
As someone who suffers from migraines, it is important for me to
understand my migraine triggers so I can stop my migraines before
they stop me," says Sparks. "That's why I'm thrilled to be teaming
up with the makers of Excedrin® Migraine to launch this
education campaign and help migraine sufferers become better
informed about their triggers and symptoms."
"I encourage all my patients who suffer from migraines to
download the My Migraine Triggers™ app," says Lenox Hill Hospital
internist and migraine sufferer Keri
Peterson, MD. "I was shocked to learn that less than half
(45%) of female migraine sufferers surveyed regularly share
migraine trigger information with their physician. The new My
Migraine Triggers™ app has a great feature which enables my
patients to send me data about their migraines before they even
walk into my office, allowing me to create a better treatment
plan."
For more tips on managing migraines visit
www.excedrin.com/migraine or find us on www.facebook.com/excedrin
or follow Excedrin® on Twitter @excedrin. As with
all medications, use Excedrin® Migraine as directed on
the package label.
About Excedrin® Migraine
The first
non-prescription medicine approved by the FDA to treat all the
symptoms of a migraine including, pain, nausea and sensitivity to
light and/or sound. Excedrin® Migraine is the #1
Neurologist recommended over-the-counter brand for migraine
relief.
About the Survey
This research was conducted
between September 7 and September 13,
2012 via an online survey of 1,000 women in the U.S.
To qualify for this survey, respondents had to indicate that they
experience migraine headaches at least four to six times per year
and have a smartphone or tablet device.
KRC Research is a full service market research firm. The
organization offers global quantitative and qualitative market
research solutions that use proven methodologies, proper sampling
techniques, and pull from over 30 years of experience interpreting
consumer feedback.
Disclaimer
The foregoing release contains
forward-looking statements including express or implied discussions
regarding potential future sales of Excedrin Migraine. You should
not place undue reliance on these statements. Such forward-looking
statements reflect the current views of management regarding future
events, and involve known and unknown risks, uncertainties and
other factors that may cause actual results to be materially
different from any future results, performance or achievements
expressed or implied by such statements. There can be no guarantee
that Excedrin Migraine will achieve any particular sales levels in
the future. In particular, management's expectations could be
affected by, among other things, unexpected manufacturing issues;
unexpected regulatory actions or delays or government regulation
generally; competition in general; the impact that the foregoing
factors could have on the values attributed to the Novartis Group's
assets and liabilities as recorded in the Group's consolidated
balance sheet, and other risks and factors referred to in Novartis
AG's current Form 20-F on file with the US Securities and Exchange
Commission. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated,
believed, estimated or expected. Novartis is providing the
information in this press release as of this date and does not
undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.
About Novartis
Novartis Consumer Health, Inc. (NCH) is
a world leader in the research, development, production and
marketing of self-medication products that do not require a
prescription. NCH products are designed for the in-home treatment
and prevention of medical conditions and ailments as well as the
enhancement of overall health and well-being.
Located in Parsippany, New
Jersey, Novartis Consumer Health, Inc. is an affiliate of
Novartis AG. Novartis provides innovative healthcare solutions that
address the evolving needs of patients and societies. Headquartered
in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative
medicines, eye care, cost-saving generic pharmaceuticals,
preventive vaccines and diagnostic tools, over-the-counter and
animal health products. Novartis is the only global company with
leading positions in these areas. In 2011, the Group's continuing
operations achieved net sales of USD 58.6
billion, while approximately USD 9.6
billion (USD 9.2 billion
excluding impairment and amortization charges) was invested in
R&D throughout the Group. Novartis Group companies employ
approximately 127,000 full-time-equivalent associates and operate
in more than 140 countries around the world. For more information,
please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at
http://twitter.com/novartis.
References
1. This research was conducted
between September 7 and September 13,
2012 via an online survey of 1,000 women in the U.S. To
qualify for this survey, respondents had to indicate that they
experience migraine headaches at least 4 to 6 times per year and
have a smartphone or tablet device.
Novartis Media Relations
|
|
|
|
Julie
Masow
Novartis
Corporation
+1 212 830
2465 (direct)
+1 862 579
8456 (mobile)
julie.masow@novartis.com
e-mail:
us.mediarelations@novartis.com
|
Milicent Brooks
Novartis
Consumer Health
+1 973 503
7483 (direct)
+1 973 479
2078 (mobile)
milicent.brooks@novartis.com
|
SOURCE Novartis Consumer Health, Inc.